Education
About Us
Working with TipRanks
Follow Us
Insmed (INSM)
NASDAQ:INSM
INSM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$21.92 - $84.91
Previous CloseN/A
Volume462.72K
Average Volume (3M)1.89M
Market Cap
$14.76B
Enterprise Value$12.38B
Total Cash (Recent Filing)$555.03M
Total Debt (Recent Filing)$45.49M
Price to Earnings (P/E)―
Beta0.94
Next Earnings
May 01, 2025EPS Estimate
-1.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.59
Shares Outstanding180,999,340
10 Day Avg. Volume2,057,450
30 Day Avg. Volume1,889,313
Standard Deviation0.20
R-Squared0.08
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)40.58
Price to Cash Flow (P/CF)-18.80
P/FCF Ratio0.00
Enterprise Value/Market Cap0.84
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit44.53
Enterprise Value/Ebitda-14.58
Forecast
1Y Price Target
$97.23Price Target Upside19.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
---
Bulls Say, Bears Say
Bulls Say
Market StrategyInsmed is focusing on education initiatives to increase awareness of brenso’s benefits and has expanded its commercial infrastructure, adding 120 sales representatives last year and planning to further strengthen its market access team.
Product LaunchInsmed has reported high levels of physician excitement ahead of brensocatib’s anticipated launch, with 90% of surveyed doctors stating they are likely to prescribe brenso for patients with two or more exacerbations.
Bears Say
Financial PerformanceEPS was below consensus estimate, likely due to higher OpEx.
---
Ownership Overview
1.28% Insiders
35.37% Mutual Funds
0.40% Other Institutional Investors
46.41% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
INSM FAQ
What was Insmed’s price range in the past 12 months?
Insmed lowest stock price was $21.92 and its highest was $84.91 in the past 12 months.
What is Insmed’s market cap?
Insmed’s market cap is $14.76B.
When is Insmed’s upcoming earnings report date?
Insmed’s upcoming earnings report date is May 01, 2025 which is in 59 days.
How were Insmed’s earnings last quarter?
Insmed released its earnings results on Feb 20, 2025. The company reported -$1.32 earnings per share for the quarter, missing the consensus estimate of -$1.171 by -$0.149.
Is Insmed overvalued?
According to Wall Street analysts Insmed’s price is currently Undervalued.
Does Insmed pay dividends?
Insmed does not currently pay dividends.
What is Insmed’s EPS estimate?
Insmed’s EPS estimate is -1.35.
How many shares outstanding does Insmed have?
Insmed has 180,999,340 shares outstanding.
What happened to Insmed’s price movement after its last earnings report?
Insmed reported an EPS of -$1.32 in its last earnings report, missing expectations of -$1.171. Following the earnings report the stock price went down -0.262%.
Which hedge fund is a major shareholder of Insmed?
Currently, no hedge funds are holding shares in INSM
---
Insmed Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$97.23 (19.23% Upside)
$97.23 (19.23% Upside)
Blogger Sentiment
Bullish
INSM Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 813.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $21.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
190.93%
12-Months-Change
Fundamentals
Return on Equity
-890.75%
Trailing 12-Months
Asset Growth
52.29%
Trailing 12-Months
Company Description
Insmed
Insmed, Inc. is a biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Its first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Its earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, NJ.
---
INSM Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a positive outlook for Insmed, highlighting record revenue growth for ARIKAYCE, successful clinical trials, and a strong cash position, despite acknowledging some challenges related to cash burn and market access strategies.Read More>---
INSM Stock 12 Month Forecast
Average Price Target
$97.23
▲(19.23% Upside)
Technical Analysis
Amicus
―
BioMarin Pharmaceutical
―
Vertex Pharmaceuticals
―
Sarepta Therapeutics
―
Ultragenyx Pharmaceutical
―
Best Analysts Covering INSM
1 Year
1 Year Success Rate
17/17 ratings generated profit
1 Year Average Return
+102.46%
reiterated a buy rating 12 days ago
Copying Jason Zemansky's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +102.46% per trade.
---